Alnylam Pharmaceuticals, Inc Forecast, price target & analysts
Alnylam Pharmaceuticals, Inc Target price 2025 - Analyst rating & recommendation
Alnylam Pharmaceuticals, Inc Classifications & Recommendation:
Alnylam Pharmaceuticals, Inc Price Target
| Target Price | $457.47 |
| Price | $429.93 |
| Potential |
6.41%
register free of charge
|
| Number of Estimates | 34 |
|
34 Analysts have issued a price target Alnylam Pharmaceuticals, Inc 2026 .
The average Alnylam Pharmaceuticals, Inc target price is $457.47.
This is
6.41%
register free of charge
$577.50
34.32%
register free of charge
$230.79
46.32%
register free of charge
|
|
| A rating was issued by 40 analysts: 31 Analysts recommend Alnylam Pharmaceuticals, Inc to buy, 8 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Alnylam Pharmaceuticals, Inc stock has an average upside potential 2026 of
6.41%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.25 | 3.01 |
| 22.97% | 33.75% | |
| EBITDA Margin | -5.35% | 7.44% |
| 57.15% | 239.15% | |
| Net Margin | -12.37% | -6.04% |
| 48.62% | 51.18% |
36 Analysts have issued a sales forecast Alnylam Pharmaceuticals, Inc 2025 . The average Alnylam Pharmaceuticals, Inc sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Alnylam Pharmaceuticals, Inc EBITDA forecast 2025. The average Alnylam Pharmaceuticals, Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
36 Alnylam Pharmaceuticals, Inc Analysts have issued a net profit forecast 2025. The average Alnylam Pharmaceuticals, Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.18 | -1.39 |
| 38.07% | 36.24% | |
| P/E | negative | |
| EV/Sales | 18.35 |
36 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast for earnings per share. The average Alnylam Pharmaceuticals, Inc EPS is
This results in the following potential growth metrics and future valuations:
Alnylam Pharmaceuticals, Inc...
Current Alnylam Pharmaceuticals, Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Aug 04 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Aug 04 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 06 2025 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Aug 04 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Aug 04 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 01 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 01 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 01 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
